The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

by Christina Demuth, Anne Tranberg Madsen, Britta Weber, Lin Wu, Peter Meldgaard, Boe Sandahl Sorensen
Published 2018-02-01

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients

by Anne Winther-Larsen, Joan Fledelius, Christina Demuth, Catharina M Bylov, Peter Meldgaard, Boe S Sorensen
Published 2016-12-01

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy

by Ninna Aggerholm-Pedersen, Christina Demuth, Akmal Safwat, Peter Meldgaard, Moustapha Kassem, Boe Sandahl Sorensen
Published 2016-01-01

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing

by Christina Demuth, Karen-Lise Garm Spindler, Julia S. Johansen, Niels Pallisgaard, Dorte Nielsen, Estrid Hogdall, Benny Vittrup, Boe Sandahl Sorensen
Published 2018-10-01

Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer

by Karen-Lise Garm Spindler, Christina Demuth, Boe Sandahl Sorensen, Julia S Johansen, Dorte Nielsen, Niels Pallisgaard, Estrid Hoegdall, Per Pfeiffer, Benny Vittrup Jensen
Published 2018-11-01